You are here

  • Home
  • Archive
  • Volume 63, Issue 9
  • Better 5-year survival of fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: still too close to call

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Better 5-year survival of fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: still too close to call
  1. Basile Njei
  1. Correspondence to Dr Basile Njei, Department of Medicine, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, Connecticut 06030-1845, USA; basilenjei{at}gmail.com

https://doi.org/10.1136/gutjnl-2013-306526

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with great interest the letter by Eggert et al, in response to our recently published article which raised concerns about the better 5-year survival of fibrolamellar hepatocellular carcinoma (fHCC) compared with conventional hepatocellular carcinoma (HCC-NOS).1 ,2 In the letter, the authors pointed out that it cannot be concluded from our meta-analysis that ‘survival in fHCC is similar to conventional HCC in non-cirrhotic liver patients’, given the overlap in the CIs of the subgroup analyses (limited to non-cirrhotic liver patients) and the overall analysis of all cases. The authors further report findings of their recently published follow-up article …

    View Full Text

    Footnotes

    • Contributors BN conceived the idea, extracted the data, carried out the analysis and wrote the manuscript.

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles